Monoamine Oxidase B in Major Depressive Disorder

单胺氧化酶 B 在重度抑郁症中的作用

• 批准号: 361529
• 负责人: Moriguchi Sho
• 金额: $ 9.83万
• 依托单位: Centre for Addiction and Mental Health (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-11-01 至 2019-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=361529&lang=en
• 关键词: Major Depressive Disorder; Monoamine Oxidase B; Mood Disorders; Positron Emission Tomography; Treatment Resistance

According to the World Health Organization, in countries like Canada, clinical depression is the leading cause of death and disability. Four per cent of Canadians suffer from clinical depression, and in half of these cases the clinical depression is treat

根据世界卫生组织的数据，在加拿大等国家，临床抑郁症是死亡和残疾的主要原因。4%的加拿大人患有临床抑郁症，其中一半的临床抑郁症得到了治疗。